| Drug Name: | Didanosine (69655-05-6) |
|---|---|
| PubChem ID: | 50599 |
| SMILES: | C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2NC=NC3=O |
| InchiKey: | BXZVVICBKDXVGW-NKWVEPMBSA-N |
| Therapeutic Category: | Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antimetabolites, Antiviral Agents, Enzyme Inhibitors, Noxae, Nucleic Acid Synthesis Inhibitors, Reverse Transcriptase Inhibitors |
| Molecular Weight (dalton) | : | 236.231 |
| LogP | : | -0.2105 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 93.03 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cytotoxicity | Cytochrome c oxidase subunit 4 (P13073) | Increase lactate production and decrease activities of COX (complex IV) and SDH (part of complex II)@are the most potent inhibitors of mitochondrial function@thus AZT@ ddI and ddC all exert Cytotoxicity on human muscle cells and induce functional alterations of mitochondria possibly due to mechanisms other than the sole mtDNA depletion [ ADR Type 1 ] | Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells |
| Cytotoxicity | SDH (Part of complex II) (P56221) | Increase lactate production and decrease activities of COX (complex IV) and SDH (part of complex II)@are the most potent inhibitors of mitochondrial function@thus AZT@ ddI and ddC all exert Cytotoxicity on human muscle cells and induce functional alterations of mitochondria possibly due to mechanisms other than the sole mtDNA depletion [ ADR Type 1 ] | Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells |
| Mtdna Depletion | DNA-directed RNA polymerase mitochondrial (O00411) | Didanosine can inhibit mitochondrial (mt)DNA polymerase and cause termination of synthesis of growing mtDNA strands and mtDNA depletion [ ADR Type 1 ] | Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells |
| Severe Hepatitis | Cytochrome P450 2E1 (P05181) | Acetaminophen enhances impaired mitochondrial oxidative metabolism and alters mitchondrial ATPase activity@which may lead to severe hepatitis. [ ADR Type 4 ] | Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature |
| Severe Pancreatitis | Cytochrome P450 2E1 (P05181) | Acetaminophen enhances impaired mitochondrial oxidative metabolism and alters mitchondrial ATPase activity@which may lead to severe pancreatitis [ ADR Type 4 ] | Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature |
| Tumor Suppression | wild-type p53 (P04637) | Those patients with a mutated p53 did not enter remission of tumor suppression following treatment with ddI and patients disease relapse was associated with the selection of a tumor clone carrying mutated inactive p53. [ ADR Type 2 ] | Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category